Gastrointestinal risk factors and patient-reported outcomes of ankylosing spondylitis in Korea

Sang Hoon Lee, Yong wook Park, Jung Yoon Choe, Kichul Shin, Seong Ryul Kwon, Jin Hye Cha, Young Joo Kim, Juneyoung Lee, Tae Hwan Kim

    Research output: Contribution to journalArticlepeer-review

    2 Citations (Scopus)


    Aim: This study examined the degree of gastrointestinal (GI) risk and patient-reported outcomes including GI-related symptoms, adherence to non-steroidal anti-inflammatory drugs (NSAIDs), disease activity and quality of life (QoL) in patients with ankylosing spondylitis (AS). Methods: Cross-sectional, observational study conducted at six nationwide, university-based hospitals of Korea. AS patients treated with NSAIDs for at least 2 weeks were included between March and September 2016. Demographic and clinical data were gathered through a medical chart review and patient survey. GI risk was estimated using Standardized Calculator of Risk for Events (SCORE). NSAIDs adherence was investigated with Morisky Medication Adherence Scale-8 (MMAS-8). Disease activity and QoL were examined with Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and EuroQol-3L (EQ-5D, EQ-visual analog scale [EQ-VAS]), respectively. Path analysis was implemented to estimate pathways of GI risk, GI symptoms and NSAIDs adherence to QoL. Results: A total of 596 patients (age: 38.9 ± 12.6 years, male: 82.1%) participated in the study, of which 33.2% experienced GI symptoms during NSAID treatment, and 34.2% of them showed ongoing GI symptoms upon enrollment. According to SCORE, 37.1% of patients showed moderate to very high GI risk. No patient showed high adherence according to MMAS-8, so 55.3% of patients with moderate adherence were considered adherent. BASDAI and QoL of the total patients were 3.5 ± 2.0, 0.6 ± 0.3 (EQ-5D), and 67.4 ± 19.8 (EQ-VAS), respectively. From path analyses, higher GI risk significantly lowered QoL. Conclusion: This study suggests timely therapeutic strategies should be implemented to manage GI risk during NSAID treatment in order to effectively manage AS.

    Original languageEnglish
    Pages (from-to)342-349
    Number of pages8
    JournalInternational journal of rheumatic diseases
    Issue number3
    Publication statusPublished - 2020 Mar 1


    • NSAID
    • ankylosing spondylitis
    • gastrointestinal risk
    • patient-reported outcomes
    • quality of life

    ASJC Scopus subject areas

    • Rheumatology


    Dive into the research topics of 'Gastrointestinal risk factors and patient-reported outcomes of ankylosing spondylitis in Korea'. Together they form a unique fingerprint.

    Cite this